ClinicalTrials.gg
RecruitingNCT03797391Updated May 31, 2023

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

A Phase 1/2 interventional study of EMB-01 in Neoplasms, Neoplasm Metastasis and Non-Small-Cell Lung Cancer, sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd.. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Dec 2018; still recruiting 7 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
186
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

Read the detailed description

This is a first-in-human (FIH), open-label, Phase I/II study of EMB-01, a bispecific Epidermal growth factor receptor (EGFR) and c-Mesenchymal-Epithelial Transition (cMet) antibody, in patients with advanced solid tumors who have progressed on available standard therapies or for which no standard therapy exists. The study consists of two parts: Phase I (dose escalation) and Phase II (cohort expansion). The study is planning to recruit tentatively 33-66 subjects with advanced/metastatic solid tumors in phase I and approximately 42-120 subjects with EGFR mutant and/or cMET aberrated NSCLC who have progressed on or are intolerant to standard treatment(s) (including platinum-based therapy) will be enrolled at the RP2D(s) in phase II part of the study. In phase II, patients will be assigned to five groups according to their molecular status at baseline. The trial will consist of molecular pre-screening period (Phase II only), clinical screening period (-28 to -1 days), treatment cycles (each cycle is 28 days, maximum up to 2 years), and safety follow-up period (30 days after the last dose).

02

Conditions studied

  • Neoplasms
  • Neoplasm Metastasis
  • Non-Small-Cell Lung Cancer

Keywords

  • Human Bispecific antibody,
  • Epidermal Growth Factor Receptor (EGFR),
  • c-Mesenchymal-Epithelial Transition (cMet),
  • Neoplasms, Neoplasm Metastasis,
  • Non-Small-Cell Lung Cancer (NSCLC), First-in-human,
  • EMB-01, Tyrosine Kinase Inhibitor (TKI) Resistant
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 186 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd. is the lead sponsor of 10 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Molecular Pre-screening Inclusion criteria (Phase II only)

  1. The patient must sign the molecular pre-screening Inform Consent to allow for the molecular pre-screening process. All patients must have documented evidence of EGFR and/or cMet aberrations.

Screening Inclusion Criteria

  1. Able to understand and willing to sign the Form (ICF).
  2. Histologically/ confirmed advanced/ solid tumors with [ (RECIST) v1.1]:

    Phase I: advanced/metastatic solid tumors including but not limited to NSCLC, colorectal cancer, gastric cancer and liver cancer to standard therapy or for which no standard therapy is available or accessible.

    Phase II: Advanced/metastatic NSCLC Patients have confirmed EGFR mutant and/or cMET aberration, and have progressed after standard treatment (including platinum-based therapy) or are intolerant to standard treatment. Additionally, patients with T790M mutation have received FDA/Health Authority approved therapies (if accessible) for this indication (i.e., osimertinib) and have progressed or became intolerant.

    A patient who has refused all currently available therapy is allowed to enroll, but must be documented in the source record.

  3. Must have adequate organ function.
  4. Regarding prior anti-tumor therapy:

    1. Must have stopped treatment at least 4 weeks or within 5 half-lives.
    2. Generalized radiation therapy must have stopped 3 weeks before first dose of EMB 01, or local radiotherapy or radiation therapy for bone metastases must have stopped 2 weeks before first dose of EMB-01. No therapeutic radiopharmaceuticals are taken within 8 weeks before first dose of EMB-01.
    3. Patients must have recovered to ≤Grade 1 from the adverse effects of such above treatment before beginning study treatment.
  5. Female patient with fertility or male patient whose partner has fertility should use one or more methods for contraception starting from screening period and continue throughout the study treatment and for 3 months.
  6. score 0 or 1 for phase I, and ≤2 for phase II.

Exclusion criteria

Exclusion Criteria:

Molecular Pre-screening Exclusion Criteria (Phase II only)

Subject who meets any of the follow criteria can't be proceeded to clinical screening:

  1. Patients who are unwilling to sign the molecular pre-screening ICF.
  2. Patients for whom local EGFR and/or cMET data or the results of central laboratory testing do not meet the molecular pre-screening inclusion criteria.

Screening Exclusion Criteria

  1. \< 3 months.
  2. Subject with primacy central nervous system (CNS) or symptomatic CNS ( or brain) .
  3. Pregnant or nursing females.
  4. Subjects who have had major surgery within 28 days prior to screening.
  5. Serious underlying medical conditions, including but not limited to un-controlled hypertension, other cardiovascular disease or diabetes, ongoing or active infection, psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere the compliance with study treatment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    Dose Escalation-Part 1, Expansion-Part 2

    In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered. In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks).

    Drug: EMB-01

Interventions

  • DrugEMB-01

    In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered. In part 2, participants will receive intravenous infusion of EMB-01 at RP2D The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks). Participants may continue to receive study drug until discontinuation criteria are met.

    Also known as: FIT-013a

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) (phase 1 only)

    Maximum tolerated dose

    Time frame: cycle 1 (1cycle = 28 days)

  2. Adverse Events (AEs), and Serious Adverse Events (SAEs)

    Adverse Events, and Serious Adverse Events

    Time frame: Screening up to follow-up (30 days after the last dose)

  3. Overall Response Rate (ORR) (phase 2 only)

    Overall Response Rate

    Time frame: From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

Secondary outcomes

  1. Maximum Serum Concentration (Cmax)

    Maximum Serum Concentration

    Time frame: Through treatment discontinuation: an average of 6 months

  2. Area Under the Plasma Concentration-Time Curve (AUC)

    Area Under the Plasma Concentration-Time Curve

    Time frame: Through treatment discontinuation: an average of 6 months

  3. Trough Serum Concentration (Ctrough)

    Trough Serum Concentration

    Time frame: Through treatment discontinuation: an average of 6 months

  4. Elimination half-life (t1/2)

    Elimination half-life

    Time frame: Through treatment discontinuation: an average of 6 months

  5. Clearance (CL)

    Clearance

    Time frame: Through treatment discontinuation: an average of 6 months

  6. Volume of distribution at steady state (Vss)

    volume of distribution at steady state

    Time frame: Through treatment discontinuation: an average of 6 months

  7. Accumulation Ratio (AR)

    Accumulation Ratio

    Time frame: hrough treatment discontinuation: an average of 6 months

  8. Dose Proportionality

    Dose Proportionality

    Time frame: Through treatment discontinuation: an average of 6 months

  9. Anti-Drug Antibodies (ADA)

    Anti-Drug Antibodies

    Time frame: Through study completion, an average of 7 months

  10. Duration Of Response (DOR)

    Duration Of Response

    Time frame: From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  11. Progression-Free Survival (PFS)

    Progression-free survival

    Time frame: Through treatment discontinuation: an average of 6 months

Other outcomes

  1. Pharmacodynamic (Soluble EGFR and cMET concentration)

    Pharmacodynamic (Soluble EGFR and cMET concentration)

    Time frame: Through treatment discontinuation: an average of 6 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Mar 2025, 75 months after the start.

Of 195 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 75 months is above that.

Counting every sponsor, half of 297 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2018
First posted
Jan 9, 2019
StartActual
Dec 13, 2018
Primary completionEst.
Mar 14, 2025
CompletionEst.
Jan 15, 2026
Last update
May 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03797391
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Collaborators
Covance
Responsible party
Sponsor
First posted
Jan 9, 2019
Start date
Dec 13, 2018
Primary completion
Mar 14, 2025 (estimated)
Completion
Jan 15, 2026 (estimated)
Last update
May 31, 2023

Study contacts

Xiaodong Sun, MD
Contact
xdsun@epimab.com
+86-21-61043299
Xuemei Xie
Contact
xmxie@epimab.com
+86-21-61043299

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bafisontamab

Start the discussion